| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Novartis is experiencing significant advancements in its product and service development, particularly highlighted by the full FDA approval of Fabhalta and a strong product pipeline. The company is demonstrating resilience through sales momentum from key drugs, which mitigates losses from generic competition. Moreover, the emphasis on upcoming drug trial results underlines the potential for further valuation increases. Overall, positive market sentiment and robust product development efforts position Novartis favorably in the pharmaceutical landscape. |
| The price action of Novartis AG (NVS) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 0.3 is modestly bullish. The market sentiment at 0.6 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. NVS is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 0.7, and the negative at -0.1 on 2026-07-21. The forces of Sentiment towards Fundamentals (2.5), Option Sentiment (1.5), Sector Price Trend (0.3), Stock Price Trend (0.3), Market Risk Appetite (0), and Price Level Sentiment (0) will drive up the price. The forces of and Valuation Sentiment (-0.3) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| NVS | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-21 | 0%(0%) | 153.87 | 1.56% | 46 | 46 | 57 | 2.89% | -0.2% | 0.3 | 0.2 | 1.2% | 0.7 | Long | 55% | 2.5 | 6.5 |
| 2026-07-20 | 0%(0%) | 149.55 | 1.79% | 8 | 36 | 20 | -2.74% | -0.39% | -0.6 | -0.7 | 1% | 0.4 | Short | 55% | 1.1 | -1 |
| 2026-07-19 | 0%(0%) | -0.4 | -0.7 | -0.4 | 0.6 | -1 | ||||||||||
| 2026-07-18 | 0%(0%) | -0.4 | -0.7 | -0.4 | 0.6 | -1 | ||||||||||
| 2026-07-17 | 0%(0%) | 153.76 | 1.9% | 49 | 47 | 65 | 0.66% | -0.39% | -0.4 | 0 | 0.8% | -0.2 | Long | 55% | 0.6 | -1 |
| 2026-07-16 | 0%(0%) | 152.74 | 1.96% | 41 | 46 | 75 | 1.3% | -0.13% | -0.1 | 0.2 | 0.6% | -0.2 | Long | 55% | -1.1 | -1 |
| 2026-07-15 | 0%(0%) | 150.78 | 2.02% | 26 | 46 | 41 | 0.28% | -0.39% | -0.7 | -0.2 | 0.7% | -0.5 | Short | 55% | -1.2 | -1 |
| 2026-07-14 | 0%(0%) | 150.36 | 2.01% | 22 | 44 | 20 | -1.98% | -0.45% | -1.1 | -0.5 | 0.8% | -0.9 | Short | 55% | -2.5 | -1 |
| 2026-07-13 | 0%(0%) | 153.39 | 1.91% | 46 | 58 | 40 | -0.43% | -0.13% | -0.3 | -0.1 | 0.4% | -0.4 | Short | 55% | -0.7 | -1 |
| 2026-07-12 | 0%(0%) | -0.3 | -0.1 | 0.7 | 2.7 | -1 | ||||||||||
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Novartis AG (NVS) Equity Research Report Wed. Mar 11, 2026 | ||
| 2026-07-21 22:48:22 The increase in core operating income and net sales highlights Novartis AG's strong financial health and growth potential. |
| 2026-07-21 22:48:22 The positive movement in Novartis AG's stock price following strong financial results indicates strong investor confidence and market performance. |
| 2026-07-21 17:13:24 The company reaffirmed its full-year guidance, indicating confidence in its overall financial performance despite pressures. |
| 2026-07-21 17:13:24 Key products contributed to the sales growth, helping to offset losses from generic competition. |
| 2026-07-21 17:13:24 CEO Vas Narasimhan expressed dedication to driving the company's future growth, signaling confidence in upcoming trials. |
| 2026-07-21 17:13:24 Ongoing pressure from generic competition was highlighted, particularly with the performance drop of the Entresto drug. |
| 2026-07-21 17:13:24 Novartis reported stronger than expected earnings for Q2, indicating stable revenue growth despite challenges. |
| 2026-07-21 09:34:46 The rise in Novartis shares due to robust earnings and growth prospects indicates optimistic investor sentiment. |
| 2026-07-21 09:34:46 The article discusses how Novartis' strategies effectively address concerns related to competition from generic drugs. |
| 2026-07-21 09:34:46 Novartis' packed pipeline and strong demand for key growth drugs are emphasized, reflecting positive product development. |
| 2026-07-21 09:34:46 The article highlights Novartis achieving better than expected Q2 earnings, indicating strong financial performance. |